

**Beneficiary Advisory Panel Handout  
Uniform Formulary Decisions  
8 January 2008**

**PURPOSE:** The purpose of this handout is to provide BAP Committee members with a reference document for the relative clinical effectiveness presentations for each Uniform Formulary (UF) Class review.

**Table 1: Uniform Formulary Recommendations from the Nov 07 DoD P&T Committee Meeting**

UF Status / Implementation Period	Generic Name (Brand)	Formulations	Generics Available?
<b>Adrenergic Beta-Blocking Agents (ABAs)</b>			
<b>Formulary</b>	<b>ABAs evaluated for Heart Failure (HF)</b>		
	Bisoprolol (Zebeta)	Tabs	Yes
	Carvedilol controlled/extended release (Coreg CR)	Caps	No
	Carvedilol immediate release (Coreg)	Tabs	Yes
	Metoprolol succinate (Toprol XL)	Tabs	Yes
	Metoprolol tartrate (Lopressor)	Tabs	Yes
	<b>Older ABAs not evaluated for HF</b>		
	Acebutolol (Sectral)	Caps	Yes
	Atenolol (Tenormin)	Tabs	Yes
	Atenolol / chlorthalidone (Tenoretic)	Tabs	Yes
	Betaxolol (Kerlone)	Tabs	Yes
	Bisoprolol / hydrochlorothiazide [HCTZ] (Ziac)	Tabs	Yes
	Labetolol (Trandate, Normodyne)	Tabs	Yes
	Metoprolol / HCTZ (Lopressor HCT)	Tabs	Yes
	Nadolol (Corgard)	Tabs	Yes
	Nadolol / benfroflumethiazide (Corzide)	Tabs	Yes
	Penbutolol (Levitol)	Tabs	Yes
	Propranolol immediate release (Inderal)	Tabs	Yes
	Propranolol extended release (Inderal LA)	Caps	Yes
	Propranolol / HCTZ (Inderide)	Tabs	Yes
	Sotalol (Betapace)	Tabs	Yes
Sotalol for atrial fibrillation (Betapace AF)	Tabs	Yes	
Timolol (Blockadren)	Tabs	Yes	
Timolol / HCTZ (Timozide)	Tabs	Yes	
<b>Non-Formulary</b>	None		
<b>Recommended implementation period</b>	N/A		
<b>Benign Prostatic Hypertrophy (BPH) Alpha Blockers (ABs)</b>			
<b>Formulary</b>	Alfuzosin ER (Uroxatral)	Tabs	No
	Terazosin (Hytrin)	Tabs / Caps	Yes
	Doxazosin (Cardura); IR and ER	Tabs	IR Yes/ER No
<b>Non-Formulary</b>	Tamsulosin (Flomax)	Caps	No
<b>Recommended implementation period</b>	60 days		

BPH: benign prostatic hypertrophy; cap: capsule; CR: controlled release; ER: extended release; HCTZ: hydrochlorothiazide; HF: heart failure; tab: tablet

**Table 1: Uniform Formulary Recommendations from the Nov 07 DoD P&T Committee Meeting (Continued)**

<b>Targeted Immunomodulatory Biologics (TIBs)</b>			
<b>UF Status / Implementation Period</b>	<b>Generic Name (Brand)</b>	<b>Formulations</b>	<b>Generics Available?</b>
<b>Formulary</b>	Adalimumab (Humira)	injection	No
	Alefacept (Amevive)	injection	No
	Efalizumab (Raptiva)	injection	No
<b>Non-Formulary</b>	Etanercept (Enbrel)	injection	No
	Anakinra (Kineret)	injection	No
<b>Recommended implementation period</b>	90 days		

**Table 2: Uniform Formulary Recommendations from the Nov 07 DoD P&T Committee Meeting for New Drugs in Classes Previously Reviewed for UF Status and New Generics**

<b>Renin Angiotensin Antihypertensives (RAAs)</b>		
<b>Recommendation at November 2007 meeting (see Table 3 for previous decisions)</b>		
<b>ARB / CCB Combinations</b>	<b>UF</b>	No change from previous meetings
	<b>Non-formulary</b>	<b>Valsartan / amlodipine (Exforge)</b> (recommended for NF November 2007)
<b>Recommended implementation period</b>	60 days	
<b>Attention Deficit Hyperactivity Disorder (ADHD) Drugs</b>		
<b>Recommendation at November 2007 meeting (see Table 4 for previous decisions)</b>		
<b>Stimulants for once daily use</b>	<b>UF</b>	No change from previous meetings
	<b>Non-formulary</b>	<b>Lisdexamfetamine (Vyvanse)</b> (recommended for NF November 2007)
<b>Recommended implementation period</b>	60 days	
<b>Contraceptives</b>		
<b>Recommendation at November 2007 meeting (see Table 5 for previous decisions)</b>		
<b>Monophasic OCs with 20 mcg EE</b>	<b>UF</b>	No change from previous meetings
	<b>Non-formulary</b>	<b>Ethinyl estradiol 20 mcg / levonorgestrel 0.09 mg Lybrel</b> (recommended for NF November 2007)
<b>Recommended implementation period</b>	60 days	
<b>Calcium Channel Blockers (CCBs)</b>		
<b>Recommendation at November 2007 meeting (see Table 6 for previous decisions)</b>		
<b>Dihydropyridine (DHP)CCBs</b>	<b>UF</b>	<b>Amlodipine (generic for Norvasc)</b>
	<b>Non-formulary</b>	Amlodipine removed from non-formulary status
<b>Recommended implementation period</b>	Immediate upon signing of the November 2007 DoD P&T Committee minutes by the Director, TMA	

**Table 3: Uniform Formulary Recommendations from Previous Meetings for Renin Angiotensin Antihypertensives (RAAs)**

<b>Existing UF Status of RAAs (previous meetings) &amp; November 2007 recommendations</b>		
<b>ARB /CCB Combinations</b>	<b>Non-Formulary</b>	<b>Valsartan / amlodipine (Exforge) (recommended for NF November 2007)</b>
Direct Renin Inhibitors	UF	Aliskiren (Tekturna)
ARBs	UF	Candesartan (Atacand)
		Candesartan /HCTZ (Atacand HCT)
		Losartan (Cozaar)
		Losartan/HCTZ (Hyzaar)
		Telmisartan (Micardis)
		Telmisartan/HCTZ (Micardis HCT)
		Candesartan (Atacand)
	Non-formulary	Eprosartan (Teveten)
		Eprosartan/HCTZ (Teveten HCT)
		Irbesartan (Avapro)
		Irbesartan/HCTZ (Avalide)
		Olmesartan (Benicar)
		Olmesartan/HCTZ (Benicar HCT)
		Valsartan (Diovan)
Valsartan/HCTZ (Diovan)		
ACE Inhibitors	UF	Benazepril and combo with HCTZ (Lotensin, Lotensin HCT)
		Captopril and combo with HCTZ (Capoten, Capozide)
		Enalapril and combo with HCTZ (Vasotec, Vaseretic)
		Fosinopril and combo with HCTZ (Monopril, Monopril HCT)
		Lisinopril and combo with HCTZ (Prinivil, Zestril, Prinzide, Zestoretic)
		Trandolapril (Mavik)
	NF	Moexipril (Univasc) and combo with HCTZ
		Perindopril (Aceon)
		Quinapril (Accupril) and combo with HCTZ
		Ramipril (Altace)
ACE/CCB Combinations	UF	Amlodipine / benazepril (Lotrel)
	Non-formulary	Felodipine / enalapril (Lexxel)
		Verapamil sustained release / trandolapril (Tarka)

ACE: Angiotensin Converting Enzyme Inhibitor; ARB: Angiotensin Receptor Blocker; CCB: Calcium Channel Blocker; HCTZ: hydrochlorothiazide

**Table 4: Uniform Formulary Recommendations from November 2006 Meeting for Attention Deficit Hyperactivity (ADHD) Drugs**

<b>Existing UF Status of ADHD Drugs (November 2006) &amp; November 2007 recommendations</b>			
<b>Formulary Status</b>	<b>Generic Name (Brand)</b>	<b>Formulations</b>	<b>Generics Available?</b>
<b>Uniform Formulary</b>	<b>ADHD Drugs</b>		
	<b>Stimulants</b>		
	<b>Once daily use products</b>		
	Methylphenidate OROS (Concerta)	tabs	No
	Mixed amphetamine salts ER (Adderall XR)	caps	No
	Methylphenidate 30% IR/70% ER (Metadate CD)	caps	No
	Methylphenidate SODAS (Ritalin LA)	caps	No
	<b>Multiple daily use products</b>		
	Methylphenidate SR (Ritalin SR)	tabs	Yes
	Methylphenidate IR (Ritalin, generics)	tabs, chew tab, oral solution	Yes (except solution and chew tab)
	Mixed Amphetamine salts (Adderall, generics)	tabs	Yes
	Dexamphetamine IR (Dexedrine, Dextrostat, generics)	tabs	Yes
	Methamphetamine IR (Desoxyn, generics)	tabs	Yes
	<b>Non-Stimulants</b>		
	Atomoxetine (Strattera)	caps	No
	<b>Narcolepsy Agents</b>		
	Modafinil (Provigil)	tabs	No
Sodium Oxybate (Xyrem)	oral solution	No	
<b>Non-Formulary</b>	<b>Lisdexamfetamine (Vyvanse) (recommended for NF at November 2007 meeting)</b>	<b>caps</b>	<b>No</b>
	Methylphenidate transdermal system (Daytrana)	patch	No
	Dexmethylphenidate IR (Focalin)	caps	No
	Dexmethylphenidate SODAS (Focalin XR)	caps	No

ER: extended release; IR: immediate release; OROS: osmotic release; SODAS: spheroidal drug absorption systems

**Table 5: Uniform Formulary Recommendations from Previous Meetings for Contraceptives**

<b>Existing UF Status of Contraceptives (May 2006) &amp; Nov 2007 recommendations</b>		
Monophasic OCs with 20 mcg EE	UF	EE 20 mcg; 0.1 mg levonorgestrel (Alesse, Levlite, generics)
		EE 20 mcg; 1.0 mg norethindrone; ferrous fumarate (Loestrin 1/20, generics)
		EE 20 mcg; 1.0 mg norethindrone (Loestrin Fe 1/20, generics)
		EE 20 mcg; 3 mg drospirinone (Yaz)
	<b>Non-formulary</b>	<b>EE 20 mg; 0.09 mg levonorgestrel (Lybrel) (recommended for NF November 2007 meeting)</b>
		EE 20 mcg; 1.0 mg norethindrone – 24-day regimen (Loestrin 24 Fe)
Monophasic OCs with 30 mcg EE	UF	EE 30 mcg; 0.15 mg levonorgestrel (Nordette, generics; excluding Seasonale)
		EE 30 mcg; 0.3 mg norgestrel (Lo-Ovral, generics)
		EE 30 mcg; 0.15 mg desogestrel (Ortho-Cept, Desogen, generics)
		EE 30 mcg; 1.5 mg norethindrone (Loestrin 1.5/30, generics)
		EE 30 mcg; 3 mg drospirinone (Yasmin)
	Non-formulary	EE 30 mcg; 0.15 mg levonorgestrel in special packaging for extended use (Seasonale, generics)
		EE 30/10 mcg; 0.15 mg levonorgestrel for extended use (Seasonique)
Monophasic OCs with 35 mcg EE	UF	EE 35 mcg; 0.5 mg norethindrone (Modicon, generics)
		EE 35 mcg; 0.25 mg norgestimate (Ortho-Cyclen, generics)
		EE 35 mcg; 1.0 mg norethindrone (Ortho-Novum 1/35, generics)
		EE 35 mcg; 1.0 mg ethynodiol diacetate (Demulen 1/35, generics)
	Non-formulary	EE 35 mcg; 0.4 mg norethindrone (Ovcon 35)
Monophasic OCs with 50 mcg EE or mestranol	UF	Mestranol 50 mcg; 1 mg norethindrone (Ortho-Novum 1.50, generics))
		EE 50 mcg; 1 mg ethynodiol diacetate (Demulen 1/50, generics)
	Non-formulary	EE 50 mcg; 0.5 mg norgestrel (Ovral, generics)
		EE 50 mcg; 1 mg norethindrone (Ovcon 50)
Biphasic OCs		EE 35 mcg; 0.5/1.0 mg norethindrone (Ortho-Novum 10/11, generics)
		EE 20/10 mcg; 0.15 mg desogestrel (Mircett, generics)
Triphasic OCs	UF	EE 25 mcg; 0.18/0.215/0.25 mg norgestimate (Ortho Tri-Cyclen Lo, generics))
		EE 35 mcg; 0.18/0.215/0.25 mg norgestimate (Ortho-Cyclen, generics)
		EE 30/40/30 mcg; 0.05/0.075/0.125 mg levonorgestrel Triphasil, generics)
		EE 35 mcg; 0.5/1/0.5 mg norethindrone (Tri-Norinyl, generics)
		EE 25 mcg; 0.1/0.125/0.15 mg desogestrel (Cyclessa, generics)
	Non-formulary	EE 20/30/35 mcg; norethindrone 1 mg (Estrostep Fe)
Progestogen-only OCs		0.35 mg norethindrone (Ortho Micronor, generics)
Patch		EE; norelgestromin (Ortho-Evra)
Vaginal ring		EE; etonorgestrel (Nuvaring)
Injectable	104 mg/ 0.65mL depot medroxyprogesterone acetate (Depo-subq Provera 104)	
	150 mg/mL depot medroxyprogesterone acetate	
Emergency contraceptives		0.75 mg levonorgestrel (Plan B)


OCs: oral contraceptives

**Table 6: Uniform Formulary Recommendation for Dihydropyridine (DHP) Calcium Channel Blockers (CCBs)**

<b>Existing UF Status of CCBs (August 2005) &amp; Nov 2007 recommendations</b>	
<b>Uniform Formulary</b>	<b>DHP CCBs</b>
	<b>Amlodipine (generic for Norvasc) (recommended for UF November 2007 meeting to remove amlodipine from non-formulary status)</b>
	Felodipine (Plendil; generics)
	Nifedipine immediate release (Procardia; generics)
	Nifedipine extended release (core coat and XL); (Procardia XL and generics)
	Nimodipine (Nimotop)
	Nisoldipine (Sular)
	<b>Non-DHP CCBs</b>
	Diltiazem immediate release (Cardizem, Tiazac; generics)
	Diltiazem sustained release (Cardizem CD; generics)
	Verapamil immediate release (Calan; Isoptin; generics)
	Verapamil sustained release (Calan SR; Isoptin SR; generics)
	<b>Non-Formulary</b>
Isradipine immediate release (DynaCirc)	
Isradipine controlled release (DynaCirc CR)	
Nicardipine immediate release (Cardene)	
Nicardipine sustained release (Cardene SR)	
<b>Non-DHP</b>	
Verapamil extended release (Verelan)	
Verapamil extended release for bedtime dosing (Verelan PM)	
Verapamil extended release for bedtime dosing (Covera HS)	
Verapamil extended release for bedtime dosing (Cardizem LA)	

Figure 1:


### MHS Utilization - Heart Failure ABAs 30-day Equivalent Rx; Nov 05 – Oct 07



Source: PIC

Figure 2:

### MHS Utilization - ABs # Rx; Oct 04 - Sep 07



Aug 05 1<sup>st</sup> UF AB review \*  
Decision date 10/13/05 → Effective date 2/15/06

Source: PD1



Table 7:

## TIB Class Definition

				Rheum				Derm	Gastro	
				RA	JRA	AS	Ps A	Plaque psoriasis	Crohn's	UC
MOA	Given									
Enbrel	Etanercept	Amgen/Wyeth	TNF	SQ (q week)	X	X	X	X	-	
Humira	Adalimumab	Abbott	TNF	SQ (qow to q week)	X	P	X	P	X (adults)	
Kineret	Anakinra	Amgen	IL-1	SQ (qd)	X					
Amevive	Alefacept	Astellas	CD-2	IM (q week)				X		
Raptiva	Efalizumab	Genentech	CD11a	SQ (q week)				X		

Not part of pharmacy benefit


Remicade	Infliximab	Centocor	TNF	IV (q 4-8 weeks)	X			X	X (adults & peds)	X
Orencia	Abatacept	BMS	CTLA 4-Ig	IV (q 4 weeks)	X					
Rituxan	Rituximab	Genentech	CD-20a	IV (days 1 & 15)	X					

RA = rheumatoid arthritis; JRA = juvenile rheumatoid arthritis; PsA = psoriatic arthritis; AS = ankylosing spondylitis; UC = ulcerative colitis

P = pending

Figure 3:


## MHS Utilization - TIBs #Rxs; Oct 04 – Sep 07




Source: PDTS

Figure 4

# What is Step Therapy?



**Figure 5: Prior Authorization Process for Benign Prostatic Hypertrophy (BPH) AB Tamsulosin (Flomax) [ABs other than Alfuzosin (Uroxatral)]**



*Note.* Alfuzosin trade name is Uroxatral

**Table 8: Uniform Formulary Implementation Plan Summary**

Meeting	Drug Class	Non-Formulary Medications	Total Beneficiaries Affected (# of patients affected)	Beneficiaries Affected by POS			Implementation Plan First Wednesday X days after the decision date	Justification	Step Therapy
				MTF	Retail	Mail Order			
Nov 07	Beta Adrenergic Receptor Blockers (ABAs)	-	0	0	0	0	N/A	No meds moved to non-formulary status	No
Nov 07	Benign Prostatic Hypertension (BPH) Alpha Blockers (ABs)	<ul style="list-style-type: none"> <li>tamsulosin (Flomax)</li> </ul>	64,783	1,426	40,161	23,196	60-days	3 <sup>rd</sup> class for Step Therapy	Yes
Nov 07	Targeted Immunomodulatory Biologics (TIBs)	<ul style="list-style-type: none"> <li>etanercept (Enbrel)</li> <li>anakinra (Kineret)</li> </ul>	7,397	1,939	4,149	1,309	90-days	Typical 90-day implementation period	No
Nov 07	Renin Antihypertensive Agents (RAAs) (New drug in previously reviewed class) (RAAs comprised of ARB/CCB combos, direct renin inhibitors, ARBs, ACE/CCB combos, ACEs)	<i>ARB/CCB combos</i> <ul style="list-style-type: none"> <li>valsartan / amlodipine (Exforge)</li> </ul>	2,376	0	2,376	0	60 days	New drug in already reviewed class with current low utilization	No
		<i>ARBs – (May 07 meeting)</i> <ul style="list-style-type: none"> <li>eprosartan (Teveten)</li> <li>eprosartan HCTZ (Teveten HCT)</li> <li>irbesartan (Avapro)</li> <li>irbesartan HCTZ (Avalide)</li> <li>olmesartan (Benicar)</li> <li>olmesartan HCTZ (Benicar HCT)</li> <li>valsartan (Diovan)</li> <li>valsartan HCTZ (Diovan HCT)</li> </ul> <i>ACE/CCB combos – Feb 06 meeting</i> <ul style="list-style-type: none"> <li>felodipine/enalapril (Lexxel)</li> <li>verapamil/trandolapril (Tarka)</li> </ul>	See previous meetings for affected beneficiaries for each subclass				See previous meetings below in table	See previous meetings below in table	

Meeting	Drug Class	Non-Formulary Medications	Total Beneficiaries Affected (# of patients affected)	Beneficiaries Affected by POS			Implementation Plan First Wednesday X days after the decision date	Justification	Step Therapy
				MTF	Retail	Mail Order			
		<ul style="list-style-type: none"> <li>ACE Inhibitors (Aug 05 meeting)</li> <li>moexipril (Univasc),</li> <li>moexipril / HCTZ (Uniretic)</li> <li>perindopril (Aceon)</li> <li>quinapril (Accupril)</li> <li>quinapril / HCTZ (Accuretic)</li> <li>ramipril (Altace)</li> </ul>							
Nov 07	Attention Deficit Hyperactivity Disorder (ADHD) / Narcolepsy agents (new drug in previously reviewed class); Previous decision Nov 06	<ul style="list-style-type: none"> <li>lisdexamfetamine (Vyvanse)</li> </ul>	2,200 Rxs	0	2,200 Rxs	0	60 days	New drug in already reviewed class with current low utilization	No
		<i>Original decision Nov 06</i> <ul style="list-style-type: none"> <li>Dexmethylphenidate IR (Focalin)</li> <li>Dexmethylphenidate SODAS (Focalin XR)</li> <li>Methylphenidate transdermal patch (Daytrana)</li> </ul>	3,078 (1.7% of patients receiving an ADHD drug)	62	2,965	51	18 Apr 07 (90 days)	Small number of beneficiaries affected	
Nov 07	Contraceptive Agents (new drug in previously reviewed class); Previous decisions May 06, Nov 06	<ul style="list-style-type: none"> <li>EE 20 mcg / levonorgestrel 0.09 mg (Lybrel)</li> </ul>	290 Rxs	2 Rxs	263 Rxs	25 Rxs	60 days	New drug in already reviewed class with current low utilization	No
		<i>Previous meetings May 06 &amp; Nov 06</i> <ul style="list-style-type: none"> <li>EE 30 mcg / levonorgestrel 0.15 mg in special packaging for extended use (Seasonale)</li> <li>EE 25 mcg / norethindrone 0.4 mg</li> </ul>	23,221 (4% of patients receiving a contraceptive)	3,128	19,249	844	24 Jan 07 (180 days)	Seasonale, packaged as a 3-month supply; Loestrin 24 FE and Seasonique	

Meeting	Drug Class	Non-Formulary Medications	Total Beneficiaries Affected (# of patients affected)	Beneficiaries Affected by POS			Implementation Plan First Wednesday X days after the decision date	Justification	Step Therapy
				MTF	Retail	Mail Order			
		<ul style="list-style-type: none"> <li>(Ovcon 35)</li> <li>EE 50 mcg / norethindrone 1 mg (Ovcon 50)</li> <li>EE 20/30/35 mcg / norethindrone 1 mg (Elostep Fe)</li> <li>EE 20 mcg/1 mg norethindrone-24 day regimen (Loestrin 24 Fe)</li> <li>EE 30/10 mcg/ 0.15 mg levonorgestrel for extended use (Seasonique)</li> </ul>	Seasonique: 161 (from Apr 06-Oct 06)	0 Rxs	112 Rxs	4 Rxs		to coincide with Seasonale decision	
			Loestrin 24 Fe: 2,227 (from Apr 06-Oct 06)	22 Rxs	3,417 Rxs	64 Rxs			
Aug 07	Nasal Corticosteroid Agents (new drug in previously reviewed class); Original decision Nov 05	<ul style="list-style-type: none"> <li>fluticasone furoate (Veramyst)</li> </ul>	650	0	650	0	TMOP & TRRx: 60-days for current users; \$22 co-pay in effect immediately for new users MTF: No later than 60 days	New drug in already reviewed class with current low utilization	No
		<i>Original Decision: Nov 05</i> <ul style="list-style-type: none"> <li>beclomethasone dipropionate (Beconase AQ, Vancenase AQ)</li> <li>budesonide (Rhinocort Aqua)</li> <li>triamcinolone (Nasacort AQ)</li> </ul>					19 Jan 06 (90 days)	Substantial number of beneficiaries	
Aug 07	Renin Antihypertensive Agents (RAAs) (RAAs new class comprised of direct renin inhibitors (Aliskiren;	<ul style="list-style-type: none"> <li>Not applicable; as Direct Renin Inhibitor aliskiren (Tekturna) was not placed non-formulary</li> </ul>	N/A	N/A	N/A	N/A	Not applicable	Aliskiren (Tekturna) not moved to non-formulary status	No
		<ul style="list-style-type: none"> <li>See Nov 07 for previous recommendations</li> </ul>							

Meeting	Drug Class	Non-Formulary Medications	Total Beneficiaries Affected (# of patients affected)	Beneficiaries Affected by POS			Implementation Plan First Wednesday X days after the decision date	Justification	Step Therapy
				MTF	Retail	Mail Order			
	Tekturna, ARBs, ACE/CCB combos, ACEs)								
Aug 07	Newer Antihistamines (NAs)	<ul style="list-style-type: none"> <li>desloratadine (Clarinet)</li> <li>desloratadine / pseudoephedrine (Clarinet D)</li> </ul>	27,396	60	20,102	7,234	TMOP & TRRx: 90-days MTF: No later than 90 days	Typical 90-day implementation period	No
Aug 07	Leukotriene Modifiers (LMs)	<ul style="list-style-type: none"> <li>zileuton (Zyflo)</li> </ul>	144	4	110	31	TMOP & TRRx: 90-days MTF: No later than 90 days	Typical 90-day implementation period	No
Aug 07	Growth Stimulating Agents (GSAs)	<ul style="list-style-type: none"> <li>somatropin (Genotropin, Genotropin Miniquick)</li> <li>somatropin (Humatrope)</li> <li>somatropin (Omnitrope)</li> <li>somatropin (Saizen)</li> </ul>	653	77	310	266	TMOP & TRRx: 60-days for current users; MTF: No later than 60 days	Low number of affected beneficiaries affected	No
May 07	Antilipidemic II Agents (LIP-2s)	<ul style="list-style-type: none"> <li>fenofibrate nanocrystallized (Tricor)</li> <li>fenofibrate micronized (Antara)</li> <li>omega-3 fatty acids (Omacor)</li> <li>colesevelam (Welchol)</li> </ul>	83,612	18,849	44,402	20,361	24 Oct 07 (90 days)	Typical 90-day implementation period	No
May 07	5-Alpha Reductase Inhibitors (5-ARIs)	<ul style="list-style-type: none"> <li>dutasteride (Avodart)</li> </ul>	20,917	1,087	12,830	7,000	24 Oct 07 (90 days)	Typical 90-day implementation period	No

Meeting	Drug Class	Non-Formulary Medications	Total Beneficiaries Affected (# of patients affected)	Beneficiaries Affected by POS			Implementation Plan First Wednesday X days after the decision date	Justification	Step Therapy
				MTF	Retail	Mail Order			
May 07 (Update from Feb 05)	PPIs	<ul style="list-style-type: none"> <li>lansoprazole (Prevacid)</li> <li>omeprazole/sodium bicarbonate (Zegerid)</li> <li>pantoprazole (Protonix)</li> <li>rabeprazole (Aciphex)</li> </ul>	453,525	212,130	178,120	63,275	24 Oct 07 (90 days)	Typical 90-day implementation period	Yes
May 07 (Update from Feb 05)	ARBs	<ul style="list-style-type: none"> <li>eprosartan (Teveten)</li> <li>eprosartan HCTZ (Teveten HCT)</li> <li>irbesartan (Avapro)</li> <li>irbesartan HCTZ (Avalide)</li> <li>olmesartan (Benicar)</li> <li>olmesartan HCTZ (Benicar HCT)</li> <li>valsartan (Diovan)</li> <li>valsartan HCTZ (Diovan HCT)</li> </ul>	228,581	68,059	109,595	50,930	21 Nov 07 (120 days)	Reservations regarding ESI ability to handle implementation	No
Feb 07	Newer Sedative Hypnotics	<ul style="list-style-type: none"> <li>Ramelteon (Rozerem)</li> <li>Zaleplon (Sonata)</li> <li>Zolpidem ER (Ambien CR)</li> </ul>	40,447	5,878	31,550	3,019	1 Aug 07 (90 days)	First time automated PA with step edit	Yes
Feb 07	Narcotic Analgesics	<ul style="list-style-type: none"> <li>Tramadol ER (Ultram ER)</li> </ul>	1,088	0	46	1,042	1 Aug 07 (90 days)	Small number of beneficiaries affected	No
Feb 07	Glaucoma Agents	<ul style="list-style-type: none"> <li>Travoprost (Travatan, Travatan Z)</li> <li>Timolol maleate (Istalol)</li> <li>Timolol hemihydrate (Betimol)</li> <li>Brinzolamide (Azopt)</li> </ul>	17,139	1,735	12,267	3,117	1 Aug 07 (90 days)	Small number of beneficiaries affected	No
Feb 07	MAOI Antidepressants	<ul style="list-style-type: none"> <li>Selegiline transdermal system (Emsam)</li> </ul>	168	0	157	11	1 Aug 07 (90 days)	Small number of beneficiaries affected	No
Nov 06	ADHD	<ul style="list-style-type: none"> <li>Dexmethylphenidate IR (Focalin)</li> <li>Dexmethylphenidate SODAS (Focalin XR)</li> <li>Methylphenidate transdermal patch (Daytrana)</li> </ul>	3,078 (1.7% of patients receiving an ADHD drug)	62	2,965	51	18 Apr 07 (90 days)	Small number of beneficiaries affected	No



Meeting	Drug Class	Non-Formulary Medications	Total Beneficiaries Affected (# of patients affected)	Beneficiaries Affected by POS			Implementation Plan First Wednesday X days after the decision date	Justification	Step Therapy
				MTF	Retail	Mail Order			
Nov 06	Older Sedative Hypnotics	-	0	0	0	0	18 Apr 07 (90 days)	No medications moved to non-formulary status	No
Aug 06	TZDs	-	0	0	0	0	Not applicable	No medications moved to non-formulary status	No
Aug 06	H2 Antagonists / GI protectants	-	0	0	0	0	Not applicable	No medications moved to non-formulary status	No
Aug 06	Antilipidemic I Agents	<ul style="list-style-type: none"> <li>▪ Rosuvastatin (Crestor)</li> <li>▪ Atorvastatin / amlodipine (Caduet)</li> </ul>	44,078	851	36,133	6,921	1 Feb 07 (90 days)	Small number of beneficiaries affected	No
May 06	Antiemetics	<ul style="list-style-type: none"> <li>▪ Dolasetron (Anzemet)</li> </ul>	852	14	668	170	27 Sept 06 (60 days)	Small number of beneficiaries affected, and acute nature of treatment (e.g., chemotherapy)	No

Meeting	Drug Class	Non-Formulary Medications	Total Beneficiaries Affected (# of patients affected)	Beneficiaries Affected by POS			Implementation Plan First Wednesday X days after the decision date	Justification	Step Therapy
				MTF	Retail	Mail Order			
May 06 update for new drugs Nov 06	Contraceptive Agents	<i>Original Decision May 06</i> <ul style="list-style-type: none"> <li>EE 30 mcg / levonorgestrel 0.15 mg in special packaging for extended use (Seasonale)</li> <li>EE 25 mcg / norethindrone 0.4 mg (Ovcon 35)</li> <li>EE 50 mcg / norethindrone 1 mg (Ovcon 50)</li> <li>EE 20/30/35 mcg / norethindrone 1 mg (Estrostep Fe)</li> </ul>	23,221 (4% of patients receiving a contraceptive)	3,128	19,249	844	24 Jan 07 (180 days)	Relatively low number of beneficiaries affected, but a high proportion are receiving Seasonale, which is packaged as a 3-month supply	No
		<i>Nov 06</i> <ul style="list-style-type: none"> <li>EE 20 mcg/1 mg norethindrone-24 day regimen (Loestrin 24 Fe)</li> <li>EE 30/10 mcg/ 0.15 mg levonorgestrel for extended use (Seasonique)</li> </ul>	Seasonique 161 (from Apr 06-Oct 06)	0 Rxs	112 Rxs	4 Rxs	Jan 24 07 (60 days; to coincide with Seasonal)	Small number of beneficiaries affected	No
		Loestrin 24 Fe: 2,227 (from Apr 06-Oct 06)	22 Rxs	3,417 Rxs	64 Rxs				
Feb 06	OABs	<ul style="list-style-type: none"> <li>tolterodine IR (Detrol)</li> <li>oxybutynin patch (Oxytrol)</li> <li>tropium (Sanctura)</li> </ul>	19,118	2,596	13,471	3,051	26 July 06 (90 days)	Recommended 60-day implementation overturned; 90-day BAP recommendation accepted	No
Feb 06	Misc Anti-hypertensive Agents	<ul style="list-style-type: none"> <li>felodipine/enalapril (Lexxel)</li> <li>verapamil/trandolapril (Tarka)</li> </ul>	5,946	336	4,472	1,138	26 July 06 (90 days)	Recommended 60-day implementation overturned; 90-day BAP recommendation accepted	No

Meeting	Drug Class	Non-Formulary Medications	Total Beneficiaries Affected (# of patients affected)	Beneficiaries Affected by POS			Implementation Plan First Wednesday X days after the decision date	Justification	Step Therapy
				MTF	Retail	Mail Order			
Feb 06	GABA-analogs	<ul style="list-style-type: none"> <li>pregabalin (Lyrica)</li> </ul>	30,649	1,120	27,566	1,963	28 Jun 06 (60 days)	Small number of beneficiaries affected	No
Nov 05	Alzheimer's Drugs	<ul style="list-style-type: none"> <li>tacrine (Cognex)</li> </ul>	5	0	3	2	19 Apr 06 (90 days)	Small number of beneficiaries affected	No
Nov 05	Nasal Corticosteroid Agents	<ul style="list-style-type: none"> <li>beclomethasone dipropionate (Beconase AQ, Vancenase AQ)</li> <li>budesonide (Rhinocort Aqua)</li> <li>triamcinolone (Nasacort AQ)</li> </ul>	96,999	13,556	73,381	10,062	19 Apr 06 (90 days)	Substantial number of beneficiaries affected	No
Nov 05	Macrolide/ Ketolide Antibiotics	<ul style="list-style-type: none"> <li>azithromycin 2 gm (Zmax)</li> <li>telithromycin (Ketek)</li> </ul>	Total number not provided; antibiotics are used to treat acute infections				22 Mar 06 (60 days)	Small number of beneficiaries affected, Medication used to treat acute (not chronic) infections not likely to require therapy change	No
Nov 05	Antidepressants I	<ul style="list-style-type: none"> <li>paroxetine HCl CR (Paxil)</li> <li>fluoxetine 90 mg for weekly administration (Prozac Weekly)</li> <li>fluoxetine in special packaging for PMDD (Sarafem)</li> <li>escitalopram (Lexapro)</li> <li>duloxetine (Cymbalta)</li> <li>bupropion extended release (Wellbutrin XL)</li> </ul>	182,916	52,624	118,582	11,710	19 Jul 06 (180 days)	Substantial number of beneficiaries affected	No
Aug 05	Alpha Blockers for BPH	<ul style="list-style-type: none"> <li>tamsulosin (Flomax)</li> </ul>	89,926	26,692	47,674	15,560	15 Feb 06 (120 days)	Substantial number of beneficiaries affected	No

Meeting	Drug Class	Non-Formulary Medications	Total Beneficiaries Affected (# of patients affected)	Beneficiaries Affected by POS			Implementation Plan First Wednesday X days after the decision date	Justification	Step Therapy
				MTF	Retail	Mail Order			
Aug 05	CCBs	<ul style="list-style-type: none"> <li>▪ amlodipine (Norvasc) <ul style="list-style-type: none"> <li>○ Nov 07: amlodipine removed from NF status</li> </ul> </li> <li>▪ isradipine IR (Dynacirc)</li> <li>▪ isradipine ER (Dynacirc CR)</li> <li>▪ nicardipine IR (Cardene, generics)</li> <li>▪ nicardipine SR (Cardene SR)</li> <li>▪ verapamil ER (Verelan)</li> <li>▪ verapamil ER for bedtime dosing (Verelan PM, Covera HS)</li> <li>▪ diltiazem ER for bedtime dosing (Cardizem LA)</li> </ul>	274,616	133,794	101,345	39,477	15 Mar 06 (150 days)	Substantial number of beneficiaries affected	No
Aug 05	ACE Inhibitors & ACE Inhibitor / HCTZ Combinations	<ul style="list-style-type: none"> <li>▪ moexipril (Univasc),</li> <li>▪ moexipril / HCTZ (Uniretic)</li> <li>▪ perindopril (Aceon)</li> <li>▪ quinapril (Accupril)</li> <li>▪ quinapril / HCTZ (Accuretic)</li> <li>▪ ramipril (Altace)</li> </ul>	158,101	77,159	57,982	22,959	16 Feb 06 (120 days)	Substantial number of beneficiaries affected	No
May 05	PDE-5 Inhibitors	<ul style="list-style-type: none"> <li>▪ sildenafil (Viagra)</li> <li>▪ tadalafil (Cialis)</li> </ul>	128,007	55,161	49,850	22,996	12 Oct 05 (90 days)	Substantial number of beneficiaries affected	No
May 05 updated for new drug Nov 06	Topical Antifungals*	<ul style="list-style-type: none"> <li>▪ econazole</li> <li>▪ ciclopirox</li> <li>▪ oxiconazole (Oxistat)</li> <li>▪ sertaconazole (Ertaczo)</li> <li>▪ sulconazole (Exelderm)</li> </ul>	49,743	14,266	33,430	2,047	17 Aug 05 (30 days)	Medication used to treat acute (not chronic) infections not likely to require therapy change	No
		<ul style="list-style-type: none"> <li>▪ miconazole 0.25%, zinc oxide 15%, white petrolatum 82.35% (Vusion)</li> </ul>	581 (Apr 06-Oct 06) (UU not applicable)	7	571	3	21 Feb 07 (60 days)	Small numbers of beneficiaries affected	No

Meeting	Drug Class	Non-Formulary Medications	Total Beneficiaries Affected (# of patients affected)	Beneficiaries Affected by POS			Implementation Plan First Wednesday X days after the decision date	Justification	Step Therapy
				MTF	Retail	Mail Order			
May 05	MS-DMDs	-	0	0	0	0	Not applicable	No medications moved to non-formulary status	No
Feb 05	ARBs	<ul style="list-style-type: none"> <li>• eprosartan (Teveten)</li> <li>• eprosartan/HCTZ (Teveten HCT)</li> </ul>	2,184	13	1,644	527	17 Jul 05 (90 days)	Recommended 30-day implementation overturned; 90-day BAP recommendation accepted	No
Feb 05	PPIs	<ul style="list-style-type: none"> <li>• esomeprazole (Nexium)</li> </ul>	138,739	6,691	117,520	14,528	17 Jul 05 (90 days)	Substantial number of beneficiaries affected	

BCF = Basic Core Formulary; ECF = Extended Core Formulary; ESI = Express-Scripts, Inc; MN = Medical Necessity; TMOP = TRICARE Mail Order Pharmacy; TRRx = TRICARE Retail Pharmacy program; UF = Uniform Formulary

CR = controlled release; ER = extended release; IR = immediate release; LA = long-acting; SR = sustained release; XL = extended release

5-ARI = 5-Alpha Reductase Inhibitors; ADHD = Attention Deficit Hyperactivity Disorder; ACE Inhibitors = Angiotensin Converting Enzyme Inhibitors; ARBs = Angiotensin Receptor Blockers; BPH = Benign Prostatic Hypertrophy; CCBs = Calcium Channel Blockers; EE = ethinyl estradiol; GSAs = Growth Stimulating Agents; GI = gastrointestinal; GABA = gamma-aminobutyric acid; H2 = Histamine-2 receptor; HCTZ = hydrochlorothiazide; Leukotriene Modifiers = LMs; LIP-1s = Antilipidemic I; LIP-2s = Antilipidemic II; MAOI = Monoamine Oxidase Inhibitor; MS-DMDs = Multiple Sclerosis Disease-Modifying Drugs; NAs = Newer Antihistamines; OABs = Overactive Bladder Medications;

PDE-5 Inhibitors = Phosphodiesterase-5 inhibitors; PMDD = Premenstrual Dysmorphic Disorder; PPIs = Proton Pump Inhibitors; RAAs = Renin Antihypertensive Agents; SODAS = spheroidal oral drug absorption system; TZDs = thiazolidinediones

\*The topical antifungal drug class excludes vaginal products and products for onychomycosis (e.g., ciclopirox topical solution [Penlac])